Frequently Asked Questions
The market is segmented based on , By Product Type (Insulin Pens, Insulin Pen Needle), Usage (Reusable Pens, Disposable Pens), Application (Type 1 Diabetes, Type 2 Diabetes), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales, Diabetes Clinics) - Industry Trends and Forecast to 2031.
.
The Global Diabetes Pen Market size was valued at USD 10.13 USD Billion in 2023.
The Global Diabetes Pen Market is projected to grow at a CAGR of 8.9% during the forecast period of 2024 to 2031.
The major players operating in the market include AstraZeneca, BD, Eli Lilly and Company, Biocon, Sanofi, Jiangsu Delfu Medical Device Co. , Owen Mumford, Wockhardt Limited, Smiths Group plc, Nipro Europe Group Companies, Novo Nordisk India , InjexUK, MannKind Corporation, BristolMyers Squibb Company, F. HoffmannLa Roche , Copernicus, Ypsomed AG, HTLSTREFA S.A., Merck & Co. , Bayer AG.
The market report covers data from the U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of the Middle East & Africa.
